Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.

Employees

979

Sector

Pharmaceuticals

Calendar

Feb. 02 - Q1 2026 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	41.41 $	+0.34%	1,352,769
26-01-15	41.27 $	+3.10%	992,634
26-01-14	40.03 $	-0.47%	1,185,630
26-01-13	40.22 $	+5.73%	1,985,280
26-01-12	38.04 $	+7.70%	1,643,778

Delayed Quote Nasdaq, January 16, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.41USD

Average target price

39.88USD

Spread / Average Target

-3.71%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
41.41 ^USD	+0.34%		+17.24%	+30.55%

Jan. 15	Twist Bioscience Insider Sold Shares Worth $931,160, According to a Recent SEC Filing	MT
Jan. 12	Twist Bioscience Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM

Capitalization	2.54B 2.19B 2.04B 1.9B 3.53B 230B 3.8B 23.42B 9.24B 110B 9.52B 9.32B 401B	P/E ratio 2026 *	-26x	P/E ratio 2027 *	-34.4x
Enterprise value	2.54B 2.19B 2.04B 1.9B 3.53B 230B 3.8B 23.42B 9.24B 110B 9.52B 9.32B 401B	EV / Sales 2026 *	5.89x	EV / Sales 2027 *	5.12x
Free-Float	97.61%	Yield 2026 *	-	Yield 2027 *	-

Jan. 15	Twist Bioscience Insider Sold Shares Worth $931,160, According to a Recent SEC Filing	MT
Jan. 12	Twist Bioscience Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM
Jan. 12	Twist Bioscience Reports 17% Rise in Preliminary Q1 Revenue	MT
Dec. 16	Aptamer Group plc Signs Licensing Agreement with Twist Bioscience	CI
Dec. 04	Twist Bioscience Introduces New Plasmid DNA Preparation Products	MT
Dec. 04	Twist Bioscience Corporation Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research	CI
Nov. 14	Twist Bioscience Corporation, Q4 2025 Earnings Call, Nov 14, 2025
Nov. 14	Twist Bioscience Fiscal Q4 Net Loss Narrows, Revenue Rises; Fiscal Q1, 2026 Revenue Outlook Issued	MT
Nov. 14	(TWST) Twist Bioscience Expects Fiscal 2026 Total Revenue Range $425M to $435M, vs. FactSet Est of $431.9M	MT
Nov. 14	(TWST) Twist Bioscience Expects Fiscal Q1 2026 Total Revenue Range $100M to $101M, vs. FactSet Est of $100.1M	MT
Nov. 14	Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q4 Revenue $99.0M, vs. FactSet Est of $97.4M	MT
Nov. 14	Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q4 Net Loss $0.45 a Share, vs. FactSet Est of $0.43 Loss	MT
Nov. 14	Twist Bioscience Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2025	CI

Nov. 04	Stephens Initiates Twist Bioscience at Overweight With $41 Price Target	MT
24-12-13	Wolfe Initiates Twist Bioscience at Outperform With $60 Price Target	MT
24-08-05	JPMorgan Raises Twist Bioscience Price Target to $35 From $28, Maintains Underweight Rating	MT
24-07-09	Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating	MT
24-06-28	Barclays Adjusts Price Target on Twist Bioscience to $60 From $45, Maintains Overweight Rating	MT

Twist Bioscience Corporation Stock

Equities

TWST

US90184D1000

Pharmaceuticals

Valuation: Twist Bioscience Corporation

Chart: Twist Bioscience Corporation

Latest news: Twist Bioscience Corporation

Last Transcript: Twist Bioscience Corporation

Analysts' recommendations: Twist Bioscience Corporation

Press Releases: Twist Bioscience Corporation

News in other languages: Twist Bioscience Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Twist Bioscience Corporation

ETFs: Twist Bioscience Corporation

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 12	Twist Bioscience : J.P. Morgan 2026 Healthcare Conference Presentation	PU
Jan. 12	Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue	BU
Dec. 18	Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference	BU
Dec. 12	Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights	BU
Dec. 04	Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research	BU

23-10-05	Bayer : a signé un accord avec Twist Bioscience
23-10-05	Bayer vereinbart Forschungs- und Lizenzvertrag mit Twist Bioscience
21-05-03	Twist Bioscience : und Vivlion gehen Partnerschaft ein, um gRNA-Bibliotheken für CRISPR-Anwendungen zu erstellen
19-10-26	Twist Bioscience : Le consortium regroupant la Fondation Praesens, l’Institut Pasteur, l’Institut Pasteur de Dakar, le Centre médical de l’université du Nebraska et Twist Bioscience a reçu le Prix Galien MedStartUp
19-04-16	Twist Bioscience : Bioscience et iGEM s’associent pour fournir de l’ADN synthétique destiné au concours et au Registre de l’iGEM

1 day	+0.34%
1 week	+17.24%
Current month	+30.55%
1 month	+29.73%
3 months	+47.05%
6 months	+17.74%
Current year	+30.55%

1 week	38.11	42.6
1 month	31	42.6
Current year	31.43	42.6
1 year	23.3	55.33
3 years	11.46	60.9
5 years	11.46	214.07
10 years	11.46	214.07

Manager	Title	Age	Since
Emily Leproust CEO	Chief Executive Officer	52	2012-12-31
Adam Laponis DFI	Director of Finance/CFO	49	2024-01-04
Patrick Finn PSD	President	54	2022-10-24

Director	Title	Age	Since
Emily Leproust CHM	Chairman	52	2022-10-24
Keith Crandell BRD	Director/Board Member	65	2013-09-30
Robert Chess BRD	Director/Board Member	67	2014-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TWIST BIOSCIENCE CORPORATION	+0.34%	+17.24%	-12.93%	+50.97%	2.54B
REGENERON PHARMACEUTICALS, INC.	-1.20%	-7.97%	+7.55%	+1.17%	75.21B
SAMSUNG BIOLOGICS CO.,LTD.	-0.92%	+94.70%	+94.70%	+94.70%	61.16B
UCB	-0.83%	+4.64%	+43.93%	+240.30%	58.53B
CSL LIMITED	+0.55%	+0.80%	-35.72%	-40.22%	56.54B
BIOGEN INC.	-2.46%	-12.37%	+16.98%	-42.00%	24.12B
INCYTE CORPORATION	+0.92%	-0.62%	+47.66%	+29.10%	20.85B
INNOVENT BIOLOGICS, INC.	-4.64%	-4.58%	+174.88%	+100.82%	19.91B
ALTEOGEN INC.	+10.10%	+1.37%	+68.46%	+1,361.21%	18.8B
MODERNA, INC.	+6.28%	+21.95%	+22.81%	-78.77%	16.34B
Average	+0.82%	+3.71%	+42.83%	+171.73%	35.4B
Weighted average by Cap.	+0.00%	+0.68%	+37.92%	+123.45%

	2026 *	2027 *
Net sales	431M 371M 346M 322M 599M 39.09B 645M 3.98B 1.57B 18.65B 1.62B 1.58B 68.08B	496M 428M 398M 371M 690M 45B 742M 4.58B 1.81B 21.47B 1.86B 1.82B 78.38B
Net income	-107M -92.08M -85.72M -79.8M -149M -9.69B -160M -986M -389M -4.62B -401M -392M -16.88B	-82.15M -70.82M -65.93M -61.38M -114M -7.45B -123M -758M -299M -3.56B -308M -302M -12.98B
Net Debt	-	-